Case Type: Mergers & Acquisitions

Turnstone Biologics Corp. (NASDAQ: TSBX) related to its sale to XOMA Royalty Corporation in which existing Turnstone shareholders will receive $0.34 in cash per share and one non-transferable contingent value right.

Guaranty Bancshares, Inc. (NYSE: GNTY) related to its sale to Glacier Bancorp, Inc. Upon completion of the proposed transaction, existing Guaranty shareholders will receive 1.0000 share of Glacier common stock for each share of Guaranty (subject to certain adjustments).

Carisma Therapeutics Inc. (NASDAQ: CARM) related to its to OrthoCellix, Inc. Upon completion of the proposed transaction, existing Carisma shareholders are expected to own approximately 10% of the combined company.

Verve Therapeutics, Inc. (NASDAQ: VERV) related to its sale to Eli Lilly. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones.

CureVac N.V. (NASDAQ: CVAC) related to its sale to BioNTech SE. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech.

Cantaloupe, Inc. (NASDAQ: CTLP) related to its sale to 365 Retail Markets, LLC for $11.20 per share in cash.

BGSF, Inc.’s (NYSE: BGSF) related to the sale of its Professional Division to INSPYR Solutions for $99 million.

M2i Global, Inc. (OTCQB: MTWO) related to its merger with Volato Group, Inc. Upon completion of the proposed merger, M2i will own approximately 90% of the combined company.

Elevation Oncology, Inc. (NASDAQ: ELEV) related to its sale to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Elevation shareholders will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% … Read more

Crown Electrokinetics Corp. (OTCMKTS: CRKN) related to its sale to Crown EK Acquisition LLC for $3.15 per share.